Moxidectin

Summary

Moxidectin (CHEMBL2104415) is an approved small molecule (ATC P02CX03); indicated across 5 conditions including onchocerciasis and helminthiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02CX03
• Indications: 5 conditions
• Clinical trials: 20
• Chemistry: 639.8 Da · C37H53NO8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104415
Name	Moxidectin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9832912
ATC	P02CX03
Molecular formula	C37H53NO8
Molecular weight	639.8
InChIKey	YZBLFMPOMVTDJY-LSGXYNIPSA-N

SMILES: C[C@@H]\1C/C(=C/C[C@@H]2C[C@@H](C[C@@]3(O2)C/C(=N\OC)/[C@@H]([C@H](O3)/C(=C/C(C)C)/C)C)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(/C(=C/C=C1)/CO5)O)O)C)/C

IUPAC name: (1R,4S,4’E,5’S,6R,6’S,8R,10E,13R,14E,16E,20R,21R,24S)-21,24-dihydroxy-4’-methoxyimino-5’,11,13,22-tetramethyl-6’-[(E)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2’-oxane]-2-one

Also known as: CL 301,423, CL-301,423, CL-301423, Moxidectin, Moxidectin component of advocate, Moxidectin for veterinary use, Moxidectina, Moxidectine, NSC-760424, SID26757123, MOXIDECTIN, SID144206940

Patent coverage: 81 distinct patent families (131 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
onchocerciasis	4	MONDO:0017137	EFO:0007402
helminthiasis	4	MONDO:0004664	EFO:1001342
strongyloidiasis	3	MONDO:0005974	EFO:0007501
filarial elephantiasis	3	MONDO:0005761	EFO:0007272

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE3	6
PHASE2	6
PHASE1	5
PHASE2/PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07145736	PHASE4	RECRUITING	Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
NCT03876262	PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
NCT00790998	PHASE3	COMPLETED	Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
NCT04056325	PHASE2/PHASE3	COMPLETED	Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
NCT04311671	PHASE3	COMPLETED	Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
NCT04410406	PHASE3	COMPLETED	Moxidectin for LF, Cote d’Ivoire (DOLF)
NCT04700423	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
NCT04848688	PHASE3	COMPLETED	Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
NCT06188715	PHASE3	COMPLETED	Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
NCT06070116	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
NCT00300768	PHASE2	COMPLETED	Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
NCT01035619	PHASE2	WITHDRAWN	Pediatric Pharmacokinetics And Safety Study Of Moxidectin
NCT03501251	PHASE2	COMPLETED	Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura
NCT03905265	PHASE2	COMPLETED	Dose-finding Study of Moxidectin for Treatment of Scabies
NCT05875441	PHASE2	COMPLETED	Efficacy and Safety Study of Moxidectin in Adults With Scabies
NCT00736697	PHASE1	COMPLETED	Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin
NCT00751764	PHASE1	COMPLETED	Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women
NCT00856362	PHASE1	COMPLETED	Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects
NCT03012828	PHASE1	COMPLETED	Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
NCT03962062	PHASE1	COMPLETED	A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).